Evaluation of Molecular Markers in Adrenal Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01348698
Recruitment Status : Terminated
First Posted : May 5, 2011
Last Update Posted : February 14, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:


- Tumors of the adrenal gland are common. Most of them are not cancerous. However, there are no tests that can accurately tell which adrenal tumors are cancerous and which are not. The only way to tell is to remove the tumor with surgery and then examine it. Researchers have been using new methods to study samples of adrenal tissue. These methods may help identify whether the cells are or may become cancerous without an operation. This information will help doctors determine which tumors will need to be removed.


- To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells.


- Individuals at least 18 years of age who have an adrenal tumor that may or may not be cancerous.


  • Participants will be screened with a physical examination, medical history, blood and urine tests, and imaging studies.
  • Participants will be examined to determine whether they have a specific type of adrenal tumor


  • Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for study.
  • Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
  • Researchers will examine the collected tissue. They will try to determine whether the cells are cancerous or may become cancerous.
  • Participants will be asked to return to the National Institutes of Health Clinical Center every year for about 5 years. During these visits they will have imaging studies, lab tests, and a physical examination.

Condition or disease
Adrenal Gland Neoplasms

Detailed Description:


  • Adrenal neoplasms are common and are incidentally discovered in 4-10% of abdominal imaging studies.
  • The majority of adrenal incidentalomas are cortical adenoma.
  • Many patients with nonfunctioning adrenal incidentalomas undergo adrenalectomy to exclude a cancer diagnosis.
  • There are no reliable clinical, radiographic or laboratory studies that accurately distinguish between localized benign and malignant adrenal neoplasm.
  • This protocol is designed to determine the feasibility and accuracy of using novel molecular markers of malignant adrenal neoplasm in fine needle aspiration (FNA) biopsy and surgically resected samples.


  • Primary Objectives:

    • To evaluate the feasibility of molecular testing in adrenal neoplasm FNA biopsy samples.
    • To determine the accuracy of novel diagnostic molecular markers in clinical adrenal FNA biopsy and surgically resected samples.
  • Secondary Objectives:

    • To analyze the gene expression level relative to disease-free survival and overall survival in patients with adrenocortical carcinoma


  • An individual with an adrenal neoplasm greater than 2cm in size
  • Age greater than or equal to 18 years
  • Adults must be able to understand and sign the informed consent document


  • Prospective observational study.
  • Demographic, clinical, laboratory and pathologic data will be collected for each patient participant. Data will be securely stored in a computerized database.
  • Patients will have biochemical testing to determine if their adrenal neoplasm is functioning or nonfunctioning.
  • After their initial on-study evaluation, patients who are found to have a nonfunctioning adrenal tumor with a low risk of malignancy will be re-screened every year for 5 years with non-invasive imaging studies.
  • Treatment of patients with an adrenal neoplasm will be performed based on standard clinical practice.
  • Projected accrual will be 50 patients per year for a total of 10 years. Thus, we anticipate accruing 500 patients on this protocol.

Study Type : Observational
Actual Enrollment : 74 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm
Study Start Date : May 4, 2011
Study Completion Date : January 12, 2018

Primary Outcome Measures :
  1. Determine feasibility of molecular testin in adrenal neoplasm FNA samples. [ Time Frame: 10 Years ]

Secondary Outcome Measures :
  1. To analyze the gene expression level relative to disease-free survivaland overall survival in patients with adrenocortical carcinoma [ Time Frame: 10 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

    1. An individual with a primary localized adrenal neoplasm greater than 2 cm in size
    2. Age greater than or equal to 18 years
    3. Adults must be able to understand and sign the informed consent document
    4. Patients must have an ECOG performance score of 0-2.
    5. Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery Note: patients with suspected but unconfirmed adrenal neoplasm may be enrolled.


  1. Biochemically proven Pheochromocytoma
  2. Women who are pregnant because of the possible side effects of radiation from CT-guided biopsies to the unborn child.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01348698

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Electron Kebebew, M.D. National Cancer Institute (NCI)

Responsible Party: National Cancer Institute (NCI) Identifier: NCT01348698     History of Changes
Other Study ID Numbers: 110149
First Posted: May 5, 2011    Key Record Dates
Last Update Posted: February 14, 2018
Last Verified: January 12, 2018

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Adrenal Cancer
Functioning Tumor
Nonfunctioning Tumor
Gene Expression
Adrenal Tumor

Additional relevant MeSH terms:
Adrenal Gland Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Adrenal Gland Diseases
Endocrine System Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents